Shirasaka T, Shimamoto Y, Oshimoto H, et al: Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 7(5): 548-557, 1996.
Salonga D, Danenberg KD, Johnson M, et al: Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehy-drogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 6(4): 1322-1327, 2000.
Ichikawa W: Prediction of clinical outcome of fluo-ropyrimidine-based chemotherapy for gastric cancer patients, in terms of the 5-fluorouracil metabolic pathway. Gastric Cancer 9(3): 145-155, 2006.